Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Visit
VJHemOnc is pleased to be the official media partner for the International Workshop on CAR-T (iwCAR-T) 2021, a high-level discussion forum for research leaders in the field of CAR-T. The world’s leading clinical researchers in the field have shared their perspectives on how to place this evolving understanding in a clinical context and thereby optimize clinical care.
iwCAR-T 2021
The International Workshop on CAR-T (iwCAR-T) 2021
21–23 April 2021 | Virtual Meeting
iwCAR-T 2021
The International Workshop on CAR-T (iwCAR-T) 2021
21–23 April 2021 | Virtual Meeting
VJHemOnc is pleased to be the official media partner for the International Workshop on CAR-T (iwCAR-T) 2021, a high-level discussion forum for research leaders in the field of CAR-T. The world’s leading clinical researchers in the field have shared their perspectives on how to place this evolving understanding in a clinical context and thereby optimize clinical care.
Session 1: CAR-T in AML
Clinical update on CAR T-cell therapy for AML
Saar Gill Perelman School of Medicine, Philadelphia, PA, United States
Role of CAR T-cells in the treatment of pediatric AML
Richard Aplenc Children's Hospital of Philadelphia, Philadelphia, PA, United States
CAR-T or BITE in AML?
Marion Subklewe LMU Hospital Munich, Munich, Germany
NK-cells and CAR NK-cells for AML
Rizwan Romee Dana-Farber Cancer Institute, Boston, MA, United States
Session 1: Panel discussion
Session 2: CAR-T in ALL
Allogeneic CAR-Ts for ALL
Reuben Benjamin King’s College Hospital, London, United Kingdom
Factors associated with durable remissions after CAR-T
Cameron Turtle Fred Hutchinson Cancer Research Center, Seattle, WA, Seattle, WA, United States
Adult ALL and CART19
Claire Roddie University College London, London, United Kingdom
Approaches to dual targeting with CAR-Ts
Nirali Shah National Cancer Institute Center for Cancer Research, Bethesda, MD, United States
Updates on neurotoxicity
Bianca Santomasso Memorial Sloan Kettering Cancer Centre, New York City, NY, United States
Session 2: Panel discussion
Session 3: CAR-T in CLL
Combining ibrutinib with CD19 CAR T-cells for CLL
Jordan Gauthier Fred Hutchinson Cancer Research Center, Seattle, WA, United States
Transcend/JCAR – lisocabtagene maraleucel (liso-cel)
Tanya Siddiqi City of Hope, Duarte, CA, United States
CAR T-cells for CLL: When can we use the word ‘cure’?
David Porter University of Pennsylvania, Philadelphia, PA, United States
Session 3: Panel discussion
Session 4: CAR-T in Myeloma
BCMA CAR-Ts – idecabtagene vicleucel (ide-cel)/bb2121
Nina Shah University of California, San Francisco, CA, United States
Ciltacabtagene autoleucel (cilta-cel) – CARTITUDE
Saad Usmani Memorial Sloan Kettering Cancer Center, New York, NY, United States
Allo-CAR-T
Sham Mailankody Memorial Sloan Kettering Cancer Centre, New York City, NY, United States
TCE – BCMA and non-BCMA targets
Adam Cohen University of Pennsylvania, Philadelphia, PA, United States
BiTEs vs CARs
Maria-Victoria Mateos University Hospital of Salamanca, Salamanca, Spain
Session 4: Panel discussion
Session 5: Evolution of Cellular Therapies
Logic-gated cell therapy
William Go A2 Biotherapeutics, Agoura Hills, CA, United States
Innovative CAR designs
Renier Bretjens Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States
Session 5: Panel discussion
Session 6: Where Are We with Emerging Cell Therapies in Solid Tumors?
alloSHRINK – non-gene edited allogeneic CAR-T in mCRC
Sébastien Anguille University of Antwerp, Antwerp, Belgium
CAR T-cells in mCRPC
Vivek Narayan University of Pennsylvania, Philadelphia, PA, United States
ROR-1 in breast and lung cancer
Jennifer Specht Seattle Cancer Care Alliance, Seattle, WA, United States
CAR T-cell therapy in glioblastoma
Christine Brown The Beckman Research Institute of City of Hope, Duarte, CA, United States
Session 6: Panel discussion (part one)
Signaling in solid tumors
Stanley Riddell Fred Hutchinson Cancer Research Center, Seattle, WA, United States
Adoptive T-cell therapy ADP-A2M4 targeting MAGE-A4
David Hong The University of Texas M.D. Anderson Cancer Center, Houston, TX, United States
Auto TILs lifileucel (LN-144) for metastatic melanoma
Amod Sarnaik H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States
Cell therapy trial updates in lung cancer and mesothelioma
Melissa Johnson Sarah Cannon Cancer Institute, Nashville, TN, United States
Session 6: Panel discussion (part two)
Session 7: CAR-T in Lymphoma
Axicabtagene ciloleucel (axi-cel) in DLBCL and FL
Caron Jacobson Dana-Farber Cancer Institute, Boston, MA, United States
Tisagenlecleucel in DLBCL/FL
Stephen Schuster Perelman School of Medicine, Philadelphia, PA, United States
Lisocabtagene maraleucel (liso-cel) in DLBCL
Jeremy Abramson Massachusetts General Hospital Cancer Center, Boston, MA, United States
Updates in MCL
Frederick Locke H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States
Dual CARs
David Miklos Stanford University, Stanford, CA, United States
Third generation CD20-targeted CAR T-cell therapy
Mazyar Shadman Fred Hutchinson Cancer Research Center, Seattle, WA, United States
A new era of targeted therapy
Sonali Smith University of Chicago, Chicago, IL, United States
Session 7: Panel discussion
Visit the CAR-T and Cellular Therapy Focus for the latest updates from leading experts
